Overview A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer Status: Not yet recruiting Trial end date: 2023-12-31 Target enrollment: Participant gender: Summary HS-10342 is a selective CDK4/6 kinase inhibitor. This study is conducted to evaluate the safety and efficacy of HS-10342 at repeated doses. Phase: Phase 2 Details Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.